Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data?

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 2, 2004, Pages 133-143

  Caldwell, Gary W ^a,b   Masucci, John A ^a   Yan, Zhengyin ^a   Hageman, William ^a  

^a J W Johnson Pharmaceutical Res I   (United States)

^b LLC   (United States)

Author keywords

Allometric Scaling; Drug Discovery; Human pharmacokinetics; Rat pharmacokinetics

Indexed keywords

ALLOMETRY; ARTICLE; CORRELATION ANALYSIS; DATA ANALYSIS; DECISION MAKING; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISCOVERY; DRUG DISTRIBUTION; DRUG HALF LIFE; IN VITRO STUDY; IN VIVO STUDY; PHARMACOKINETICS; STEADY STATE; SYSTEMIC CIRCULATION;

EID: 3042575812     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190588     Document Type: Article

References (54)

1. Caldwell, J. (1996). The importance of drug metabolism studies for efficient drug discovery and development. Yakubutsu Dotai 11(1), 119-26.
2. Smith, D. A.; Jones, B. C.; Walker, D. K. (1996). Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16(3), 243-266.
3. Rodrigues, A. D. (1997). Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. Pharm Res 14(11), 1504-1510.
4. Tarit, M. H.; Berman, J. (1998). High-throughput approaches for evaluating absorption distribution, metabolism and excretion properties of lead compounds. Curr Opin in Chem Bio 2, 411-416.
5. Sinko, P. J. (1999). Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr Opin in Drug Discov Develop 2(1), 42-48.
6. Caldwell, G. W. (2000). Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. [Published erratum appears in Curr Opin in Drug Discov Develop 2000, 3(2), 250]. Curr Opin in Drug Discov Devel 3(1), 30-41.
7. Caldwell, G. W. (2000). Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. [Published erratum appears in Curr Opin in Drug Discov Develop 2000, 3(2), 250]. Curr Opin in Drug Discov Devel 3(1), 30-41.
8. Caldwell, G. W.; Ritchie, D. M.; Masucci, J. A.; Hageman, W. (2001). The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr Top in Med Chem 1(5), 353-366.
9. Robert, S. A. (2003). Drug metabolism and pharmacokinetics in drug discovery. Curr Opin in Drug Discov Develop 6(1), 66-80.
10. Caldwell, G. W.; Yan, Z.; Masucci, J. A.; Hageman, W.; Ritchie, D. M. (2003). Applied Pharmacokinetics in Drug Development. An Overview of Drug Discovery. Pharm Dev Regul 1(2), 117-132.
11. Macdonald, S. J. F.; Smith, P. W. (2001). Lead optimization in 12 months? True confessions of a chemistry team. Drug Discov Today 6(18), 947-953.
12. Bachmann, K. A.; Ghoshh, R. (2001). The use of in-vitro methods to predict in-vivo pharmacokinetics and drug interactions. Curr Drug Metab 2, 299-314.
13. Smith, D.; Schmid, E.; Jones, B. (2002). Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery? Clin Pharmacokinet 41(13), 1005-1019.
14. Obach, R. S; Baxter, J G.; Liston, T E.; Silber, B. M; Jones, B C.; Macintyre, F; Rance, D J.; Wastall, P. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283(1), 46-58.
15. Obach, R. S. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27(11), 1350-1359.
16. Obach R. S (2001). The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin in Drug Discov Develop 4(1), 36-44.
17. McGinnity, D. F.; Riley, R. J. (2001). Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochemical Society Transactions 29(2), 135-139.
18. Lave, Th.; Dupin, S.; Schmitt, C., Valles, B.; Ubeaud, G.; Chou, R. C.; Jaeck, D.; Coassolo, Ph. (1997). The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 14(2), 152-155.
19. Caldwell, G. W.; Masucci, J. A.; Chacon, E. (1999). High throughput liquid chromatography-mass spectrometry assessment of the metabolic activity of commercially available hepatocytes from 96-well plates. Comb Chem High Throughput Screening 2(1), 39-51.
20. Lau, Y. Y.; Sapidou, E.; Cui, X.; White, R. E.; Cheng, K.-C. (2002). Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos 30(12), 1446-1454.
21. Iwatsubo T.; Hirota N.; Ooie T.; Suzuki H.; Shimada N.; Chiba K.; Ishizaki T.; Green C. E.; Tyson C.A.; Sugiyama Y. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73(2), 5147-171.
22. Lombardo, F.; Obach, R. S.; Shalaeva, M. Y.; Gao, F. (2002). Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 45, 2867-2876.
23. Hosseini-Yeganeh, M.; McLachlan, A. J. (2002). Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicro Agents Chemother 46(7), 2219-2228.
24. Mahmood, I. (1999). Allometric Issues in Drug Development. J Pharm Sci 88(11), 1101-1106.
25. Feng, M. R.; Lou, X.; Brown, R. R.; Hutchaleelaha, A. (2000). Allometric Pharmacokinetics Scaling. Towards the Prediction of Human Oral pharmacokinetics. Pharm Res, 17(4), 410-418.
26. Boxenbaum, H. (1982). Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. J. Pharmacokinet Biopharm 10, 201-227.
27. Cox, K. A.; Dunn-Meynell, K.; Korfmacher, W. A.; Broske, L.; Nomeir, A. A.; Lin, C.-C.; Cayen, M. N.; Barr, W. H. (1999). Novel in-vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats. Drug Discov Today 4(5), 232-237.
28. Hu, T.-M.; Hayton, W. L. (2001). Allometric scaling of xenobiotic clearance: uncertainty versus universality. PharmSci [online computer file; www.pharmsci.org/scientificjournals/pharmsci/journal/01-29.html] 3(4), Article 29.
29. Chiou, W. L.; Robbie, G.; Chung, S. M.; Wu, T-C.; Ma, C. (1998). Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharm Res 15(9), 1474-1479.
30. Lave, T.; Coassolo, P.; Reigner, B. (1999). Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 36(3), 211-231.
31. Wajima, T.; Fukumura, K.; Yano, Y.; Oguma, T. (2002). Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J Pharm Sci 91(12), 2489-2499.
32. Mahmood, I. (1999). Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. J Pharm Pharmacol 51(8), 905-910.
33. Mahmood, I.; Balian, J. D. (1996). Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 593, 579-585.
34. Szakacs, T; Veres, Z; Vereczkey, L. (2001). In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. Polish J Pharmacol 53(6), 623-628.
35. Spasov, A. A.; Stepanov, A. V.; Smirnova, L. A.; Petrov, V. I.; Shabasheva, I. G. (2002). Pharmacokinetics of rhythmidazol upon single intravenous administration. Eksperimental'naya i Klinicheskaya Farmakologiya 65(3), 57-61.
36. Beaumont, K.; Harper, A.; Smith, D. A.; Bennett, J. (2000). The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. Eur J Pharm Sci 12(1), 41-50.
37. Sukbuntherng, J; Cropp, G; Hannah, A; Wagner, G S.; Shawver, L K.; Antonian, L (2001). Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm and Pharmacol 53(12), 1629-1636.
38. Iavarone, L.; Hoke, J. F.; Bottacini, M.; Barnaby, R.; Preston, G. C. (1999). First time in human for GV 196771: interspecies scaling applied on dose selection. J Clin Pharmacol 39(6), 560-566.
39. Mahmood, I. (1998). Interspecies scaling: Predicting volumes, mean residence time and elimination half-life. Some suggestions. J Pharm Pharmacol 50, 493-499.
40. Bachmann, K; Pardoe, D; White, D. (1996) Scaling basic toxicokinetic parameters from rat to human. Environ Health Perspect 104(4), 400-407.
41. Bachmann, K. (1989). Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species, J Appl Toxicol 9(5), 331-8.
42. Vo_eh, S.; Schmidlin, O.; Taeschner, W. (1989). Pharmacokinetic drug Data. In: Clinical Pharmacokinetic Drug Data Handbook 1989. ADIS Press Limited, New Zealand, p. 1-38.
43. Travis, C. C.; White, Robin K.; Ward, Richard C. (1990). Interspecies extrapolation of pharmacokinetics. J Theor Biol, 142(3), 285-304.
44. Fan, A.; Howd, R.; Davis, B. (1995). Risk assessment of environmental chemicals. Ann Rev Pharmacol Toxicol, 35, 341-68.
45. Sanford, B., 1997. In: James Swarbrick (ed.) Pharmaceutical statistics: practical and clinical applications. Marcel Dekker Inc. New York, p. 17.
46. Sietsema, W K. (1989). The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 27(4), 179-211.
47. Chiou, W. L.; Buehler, P W. (2002). Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human. Pharm Res 19(6), 868-874.
48. Mahmood, I. (2000). Can absolute oral bioavailability in humans be predicted from animals? A comparison of allometry and different indirect methods. Drug Metab Drug Int 16(2), 143-155.
49. Chiou, W. L.; Barve, A. (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 5(11), 1792-1795.
50. Chiou, W. L.; Ma, C.; Chung, S. M.; Wu, T. C.; Jeong, H. Y. (2000). Similarity in the linear and non-linear oral absorption of drugs between human and rat. Inter J Clin Pharmacol Ther 38(11), 532-539.
51. Chiou, W. L.; Jeong, Hyun Y.; Chung, Sang M.; Wu, Ta C. (2000). Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17(2), 135-140.
52. Amidon, G. L.; Sinko, P. J.; Fleisher, D (1988). Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res 5(10), 651-4.
53. Mahmood, I. (1998). Interspecies scaling of renally secreted drugs. Life Sci. 63, 2365-2371.
54. Sarver, J G.; White, D; Erhardt, P; Bachmann, K. (1997). Estimating xenobiotic half-lives in humans from rat data: influence of log P. Environ Health Perspect 105(11); 1204-1209.